Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.
Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.
复制标题
DOI：
10.1007/s00125-016-4100-7
复制
发表时间：
2016-12
期刊：
影响因子：
8.2
通讯作者：
Cahen DL
中科院分区：
文献类型：
--
作者：
Smits MM;Tonneijck L;Muskiet MH;Kramer MH;Pouwels PJ;Pieters-van den Bos IC;Hoekstra T;Diamant M;van Raalte DH;Cahen DL
已建议基于胰高血糖素样肽（GLP）-1的治疗可改善肝脂肪变性。我们评估了GLP-1受体激动剂利拉鲁肽和二肽基肽酶（DPP）-4抑制剂西格列汀对2型糖尿病患者肝脂肪变性和纤维化的影响。这项为期12周的平行、随机、安慰剂对照试验于2013年7月至2015年8月在VU大学医学中心进行，52例接受二甲双胍和/或磺脲类药物治疗的超重2型糖尿病患者（[平均值± SD]年龄62.7 ± 6.9岁，HbA 1c 7.3 ± 0.7%或56 ± 1 mmol/mol）分配至利拉鲁肽1.8 mg每日一次组（n = 17），西格列汀100 mg（n = 18）或匹配安慰剂（n = 17）通过计算机生成的数字。参与者和研究人员都对分组不知情。采用质子磁共振波谱（1H-MRS）测量肝脏脂肪含量。使用三个经验证的公式估计肝纤维化。西格列汀组有1例患者因头晕退出，但未发生严重不良事件。第12周时，未发现肝脂肪变性的组间差异，利拉鲁肽使脂肪变性减少10%（20.9 ± 3.4%至18.8 ± 3.3%），西格列汀使脂肪变性减少12.1%（23.9 ± 3.0%至21.0 ± 2.7%），安慰剂使脂肪变性减少9.5%（18.7 ± 2.7%至16.9 ± 2.7%）。与安慰剂相比，两种药物均不影响肝纤维化评分。利拉鲁肽或西格列汀治疗10周不能减少2型糖尿病患者的肝脂肪变性或纤维化。ClinicalTrials.gov NCT 01744236由欧洲共同体第七框架计划（FP 7/2007-2013）根据第282521号赠款协议资助-SAFEGUARD项目。本文的在线版本（doi：10.1007/s 00125 -016-4100-7）包含同行评审但未经编辑的补充材料，可供授权用户使用。
Glucagon-like peptide (GLP)-1-based therapies have been suggested to improve hepatic steatosis. We assessed the effects of the GLP-1 receptor agonist liraglutide and the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin on hepatic steatosis and fibrosis in patients with type 2 diabetes. In this 12 week, parallel, randomised, placebo-controlled trial, performed at the VU University Medical Center between July 2013 and August 2015, 52 overweight patients with type 2 diabetes treated with metformin and/or sulphonylurea agent ([mean ± SD] age 62.7 ± 6.9 years, HbA1c 7.3 ± 0.7% or 56 ± 1 mmol/mol) were allocated to once daily liraglutide 1.8 mg (n = 17), sitagliptin 100 mg (n = 18) or matching placebos (n = 17) by computer generated numbers. Both participants and researchers were blinded to group assignment. Hepatic fat content was measured using proton magnetic resonance spectroscopy (1H-MRS). Hepatic fibrosis was estimated using three validated formulae. One patient dropped out in the sitagliptin group owing to dizziness, but no serious adverse events occurred. At week 12, no between-group differences in hepatic steatosis were found. Liraglutide reduced steatosis by 10% (20.9 ± 3.4% to 18.8 ± 3.3%), sitagliptin reduced steatosis by 12.1% (23.9 ± 3.0% to 21.0 ± 2.7%) and placebo lessened it by 9.5% (18.7 ± 2.7% to 16.9 ± 2.7%). Neither drug affected hepatic fibrosis scores compared with placebo. Twelve-week liraglutide or sitagliptin treatment does not reduce hepatic steatosis or fibrosis in type 2 diabetes. ClinicalTrials.gov NCT01744236 Funded by the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 282521 – the SAFEGUARD project. The online version of this article (doi:10.1007/s00125-016-4100-7) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
登录
查看更多内容
影响因子：
3.7
作者：
Cuthbertson DJ;Irwin A;Gardner CJ;Daousi C;Purewal T;Furlong N;Goenka N;Thomas EL;Adams VL;Pushpakom SP;Pirmohamed M;Kemp GJ
通讯作者：
Kemp GJ
影响因子：
13.5
作者：
Kim, Donghee;Kim, W. Ray;Kim, Hwa Jung;Therneau, Terry M.
通讯作者：
Therneau, Terry M.
影响因子：
25.7
作者：
Dulai PS;Sirlin CB;Loomba R
通讯作者：
Loomba R
DOI：
10.1056/nejmoa1603827
发表时间：
2016-07-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Marso SP;Daniels GH;Brown-Frandsen K;Kristensen P;Mann JF;Nauck MA;Nissen SE;Pocock S;Poulter NR;Ravn LS;Steinberg WM;Stockner M;Zinman B;Bergenstal RM;Buse JB;LEADER Steering Committee;LEADER Trial Investigators
通讯作者：
LEADER Trial Investigators
影响因子：
3.7
作者：
Potts JE;Gray LJ;Brady EM;Khunti K;Davies MJ;Bodicoat DH
通讯作者：
Bodicoat DH